R&D In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cell Therapeutics completes enrollment in pixantrone Phase III trial; Elixir Pharmaceuticals type 2 drug mitiglinide enters final Phase III; Takeda stops development of cholesterol compound TAK-475 (lapaquistat); more R&D news, in brief
You may also be interested in...
Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan
Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan
R&D IN BRIEF
QuatRx starts second pivotal trial for its SERM Ophena; Arcalyst significantly reduces gout flares; Novartis dumps antibiotic add-on Aurograb; more R&D, in brief